Epigenetics of hematopoiesis and hematological malignancies
Open accessThe DOI matches its Crossref record; 251 of the 251 references it cites were found in a registry or an index.
Abstract
Hematological malignancies comprise a diverse set of lymphoid and myeloid neoplasms in which normal hematopoiesis has gone awry and together account for ∼10% of all new cancer cases diagnosed in the United States in 2016. Recent intensive genomic sequencing of hematopoietic malignancies has identified recurrent mutations in genes that encode regulators of chromatin structure and function, highlighting the central role that aberrant epigenetic regulation plays in the pathogenesis of these neoplasms. Deciphering the molecular mechanisms for how alterations in epigenetic modifiers, specifically histone and DNA methylases and demethylases, drive hematopoietic cancer could provide new avenues for developing novel targeted epigenetic therapies for treating hematological malignancies. Just as past studies of blood cancers led to pioneering discoveries relevant to other cancers, determining the contribution of epigenetic modifiers in hematologic cancers could also have a broader impact on our understanding of the pathogenesis of solid tumors in which these factors are mutated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Herrera-Merchan, A., Arranz, L., Ligos, J., de Molina, A., Domínguez, O., & González, S. (2012) · Nature Communications · doi:10.1038/ncomms1623 · Cited by 141
RetractedShrestha, S., & Offer, S. M. (2016) · Medical Epigenetics · doi:10.1159/000444713 · Cited by 8,914
Conversion of 5-Methylcytosine to 5-Hydroxymethylcytosine in Mammalian DNA by MLL Partner TET1
Tahiliani, M., Koh, K. P., Shen, Y., Pastor, W. A., Bandukwala, H., Brudno, Y., Agarwal, S., Iyer, L. M., Liu, D. R., Aravind, L., et al. (2009) · Science · doi:10.1126/science.1170116 · Cited by 5,836 · cited 4×
“…of dioxygenases that use oxygen, Fe(II), and a-ketoglutarate as substrates in a sequential enzymatic reaction to convert 5-methylcytosine (5mC) into 5-hydroxymethylcytosine (5hmC) and subsequently into 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC) (Iyer et al. 2009; Tahiliani et al. 2009).”
BackgroundInfluentialChen, X., Xiu, M., Xing, J., Yu, S., Min, D., & Guo, F. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000479439 · Cited by 5,742
Mutational landscape and significance across 12 major cancer types
Kandoth, C., McLellan, M. D., Vandin, F., Ye, K., Niu, B., Lu, C., Xie, M., Zhang, Q., McMichael, J. F., Wyczalkowski, M. A., et al. (2013) · Nature · doi:10.1038/nature12634 · Cited by 4,419 · cited 1×
“MLL4 (GeneID 8085) mutations are prevalent in NHL (Morin et al. 2011; Pasqualucci et al. 2011; Lohr et al. 2012; Green et al. 2015), ALL (Mar et al. 2012; Lindqvist et al. 2015; Neumann et al. 2015), and AML (Kandoth et al. 2013).”
BackgroundHistone H3K27ac separates active from poised enhancers and predicts developmental state
Creyghton, M. P., Cheng, A. W., Welstead, G. G., Kooistra, T., Carey, B. W., Steine, E. J., Hanna, J., Lodato, M. A., Frampton, G. M., Sharp, P. A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016071107 · Cited by 4,302
Selective inhibition of BET bromodomains
Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262 · cited 1×
“Last, the oncogenic potential of NSD3 was first suggested by the observation that it was overexpressed in breast cancer and was later found as a fusion partner of the NUT oncogene in midline carcinoma (Filippakopoulos et al. 2010).”
BackgroundA gene complex controlling segmentation in Drosophila
Lewis, E. B. (1978) · Nature · doi:10.1038/276565a0 · Cited by 3,812 · cited 1×
“…malignant hematopoiesis PcG proteins were initially identified in Drosophila by mutations that cause homeotic transformations, such as GENES & DEVELOPMENT 2027 leg-to-antenna transformations or the appearance of additional sex combs on the second and third pairs of legs (Lewis 1978; Struhl 1981).”
BackgroundRole of Histone H3 Lysine 27 Methylation in Polycomb-Group Silencing
Cao, R., Wang, L., Wang, H., Xia, L., Erdjument-Bromage, H., Tempst, P., Jones, R. S., & Zhang, Y. (2002) · Science · doi:10.1126/science.1076997 · Cited by 3,775 · cited 1×
“The chromobox (CBX) proteins have a chromodomain that recognizes the H3K27me3 mark implemented by PRC2 and mediates the chromatin targeting of the canonical PRC1 complex (Cao et al. 2002; Fischle et al. 2003; Min et al. 2003; Agger et al. 2007; Lee et al. 2007).”
BackgroundTet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine
Ito, S., Shen, L., Dai, Q., Wu, S. C., Collins, L. B., Swenberg, J. A., He, C., & Zhang, Y. (2011) · Science · doi:10.1126/science.1210597 · Cited by 3,451 · cited 2×
“4A; He et al. 2011; Ito et al. 2011).”
BackgroundHeintzman, N. D., Stuart, R. K., Hon, G., Fu, Y., Ching, C. W., Hawkins, R. D., Barrera, L. O., Van Calcar, S., Qu, C., Ching, K. A., et al. (2007) · Nature Genetics · doi:10.1038/ng1966 · Cited by 3,398 · cited 2×
“Histone H3K4me1 alone marks enhancers before their activation (Heintzman et al. 2007), with the addition GENES & DEVELOPMENT 2025 ofH3K27ac indicating active enhancers.”
BackgroundThe Polycomb complex PRC2 and its mark in life
Margueron, R., & Reinberg, D. (2011) · Nature · doi:10.1038/nature09784 · Cited by 3,347 · cited 1×
“3C;Margueron et al. 2008).”
Discovery and saturation analysis of cancer genes across 21 tumour types
Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G. (2014) · Nature · doi:10.1038/nature12912 · Cited by 3,096 · cited 1×
“Indeed, high-throughput, genome-scale sequencing has revealed that chromatinmodifiers are among themost frequently mutated in cancer in general, particularly in he- matological malignancies, suggesting prominent roles played by the epigenetic alterations in these diseases (Lawrence et al. 2014).”
BackgroundTet-Mediated Formation of 5-Carboxylcytosine and Its Excision by TDG in Mammalian DNA
He, Y.-F., Li, B.-Z., Li, Z., Liu, P., Wang, Y., Tang, Q., Ding, J., Jia, Y., Chen, Z., Li, L., et al. (2011) · Science · doi:10.1126/science.1210944 · Cited by 2,770 · cited 1×
“4A; He et al. 2011; Ito et al. 2011).”
The polycomb group protein EZH2 is involved in progression of prostate cancer
Varambally, S., Dhanasekaran, S. M., Zhou, M., Barrette, T. R., Kumar-Sinha, C., Sanda, M. G., Ghosh, D., Pienta, K. J., Sewalt, R. G. A. B., Otte, A. P., et al. (2002) · Nature · doi:10.1038/nature01075 · Cited by 2,717
Hematopoiesis: An Evolving Paradigm for Stem Cell Biology
Orkin, S. H., & Zon, L. I. (2008) · Cell · doi:10.1016/j.cell.2008.01.025 · Cited by 2,570 · cited 1×
“1A; Moore and Metcalf 1970; Lux et al. 2008; Orkin and Zon 2008; Baron et al. 2012; Cullen et al. 2014).”
BackgroundHistone modifications at human enhancers reflect global cell-type-specific gene expression
Heintzman, N. D., Hon, G. C., Hawkins, R. D., Kheradpour, P., Stark, A., Harp, L. F., Ye, Z., Lee, L. K., Stuart, R. K., Ching, C. W., et al. (2009) · Nature · doi:10.1038/nature07829 · Cited by 2,533 · cited 1×
“A high level of H3K4monomethylation (H3K4me1) with a relatively low level of H3K4me3 trimethylation (H3K4me3) has been identified as a signature of enhancers (Heintzman et al. 2007, 2009).”
BackgroundPolycomb complexes repress developmental regulators in murine embryonic stem cells
Boyer, L. A., Plath, K., Zeitlinger, J., Brambrink, T., Medeiros, L. A., Lee, T. I., Levine, S. S., Wernig, M., Tajonar, A., Ray, M. K., et al. (2006) · Nature · doi:10.1038/nature04733 · Cited by 2,514 · cited 1×
“PRC1 and PRC2 co-occupy many PcG target loci and play crucial roles in their reciprocal recruitment to chromatin (Boyer et al. 2006; Schwartz et al. 2006; Ku et al. 2008).”
BackgroundA unique chromatin signature uncovers early developmental enhancers in humans
Rada-Iglesias, A., Bajpai, R., Swigut, T., Brugmann, S. A., Flynn, R. A., & Wysocka, J. (2011) · Nature · doi:10.1038/nature09692 · Cited by 2,233 · cited 1×
“Poised enhancers are distinguished by the presence of H3K27me3 and are found primarily in stem and progenitor cells, transitioning to active enhancers upon differentiation cues (Creyghton et al. 2010; Rada-Iglesias et al. 2011).”
BackgroundDNMT3A Mutations in Acute Myeloid Leukemia
Ley, T. J., Ding, L., Walter, M. J., McLellan, M. D., Lamprecht, T., Larson, D. E., Kandoth, C., Payton, J. E., Baty, J., Welch, J., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1005143 · Cited by 1,983
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
Patel, J. P., Gönen, M., Figueroa, M. E., Fernandez, H., Sun, Z., Racevskis, J., Van Vlierberghe, P., Dolgalev, I., Thomas, S., Aminova, O., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112304 · Cited by 1,946
An operational definition of epigenetics: Figure 1.
Berger, S. L., Kouzarides, T., Shiekhattar, R., & Shilatifard, A. (2009) · Genes & Development · doi:10.1101/gad.1787609 · Cited by 1,884 · cited 1×
“The term “epigenetics” was coined by developmental biologist Conrad Waddington to describe heritable changes in the cellular phenotype and gene expression that are independent of alterations in the DNA sequence during embryonic development (Slack 2002; Berger et al. 2009).”
BackgroundSelf-citationBmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells.
Park, I.-K., Qian, D., Kiel, M., Becker, M. W., Pihalja, M., Weissman, I. L., Morrison, S. J., & Clarke, M. F. (2003) · Nature · doi:10.1038/nature01587 · Cited by 1,871 · cited 3×
“The homozygous deletion of Bmi1 in mice decreases the number of HSCs by inducing symmetrical division, derepression of the Ink4a–Arf locus (encoding p16INK4A and p19ARF proteins), and generation of ROS andDNAdamage (Park et al. 2003; Iwama et al. 2004; Oguro et al. 2006; Liu et al. 2009).”
BackgroundEZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
McCabe, M. T., Ott, H. M., Ganji, G., Korenchuk, S., Thompson, C., Van Aller, G. S., Liu, Y., Graves, A. P., III, A. D. P., Diaz, E., et al. (2012) · Nature · doi:10.1038/nature11606 · Cited by 1,786 · cited 2×
“Indeed, recurrent somatic mutations that result in increased EZH2 enzymatic activity have been observed in lymphoma (Morin et al. 2011; Yap et al. 2011; McCabe et al. 2012a).”
BackgroundDalla-Favera, R., Bregni, M., Erikson, J., Patterson, D., Gallo, R. C., & Croce, C. M. (1982) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.79.24.7824 · Cited by 1,773 · cited 1×
“…is the chromosomal translocation commonly found in Burkitt’s lymphoma that places theMYC oncogene under the control of an immunoglobulin heavy chain (Igh) enhancer, leading to the uncontrolled expression of MYC and the development of lymphoma (Dalla-Favera et al. 1982; Park et al. 2005).”
BackgroundCloning and characterization of a family of novel mammalian DNA (cytosine-5) methyltransferases
Okano, M., Xie, S., & Li, E. (1998) · Nature Genetics · doi:10.1038/890 · Cited by 1,651 · cited 5×
“DNMT3A and DNMT3B function as de novo DNA methyltransferases, which can methylate the unmethylated cytosines during embryogenesis (Fig. 4A; Stein et al. 1982; Okano et al. 1998; Jones and Liang 2009).”
BackgroundInfluentialKleer, C. G., Cao, Q., Varambally, S., Shen, R., Ota, I., Tomlins, S. A., Ghosh, D., Sewalt, R. G. A. B., Otte, A. P., Hayes, D. F., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1933744100 · Cited by 1,649 · cited 1×
“EZH2 overexpression is commonly observed in various epithelial malignancies, including breast and prostate cancer, suggesting that EZH2 functions as an oncogene (Varambally et al. 2002; Kleer et al. 2003; Li et al. 2009a).”
BackgroundClinical Effect of Point Mutations in Myelodysplastic Syndromes
Bejar, R., Stevenson, K., Abdel-Wahab, O., Galili, N., Nilsson, B., Garcia-Manero, G., Kantarjian, H., Raza, A., Levine, R. L., Neuberg, D., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1013343 · Cited by 1,627 · cited 1×
“The mutations of ASXL1 are associated with a dismal overall prognosis in patients with MDS and AML (Abdel-Wahab et al. 2011, 2012; Bejar et al. 2011; Patel et al. 2012).”
BackgroundFrequent mutation of histone-modifying genes in non-Hodgkin lymphoma
Morin, R. D., Mendez-Lago, M., Mungall, A. J., Goya, R., Mungall, K. L., Corbett, R. D., Johnson, N. A., Severson, T. M., Chiu, R., Field, M., et al. (2011) · Nature · doi:10.1038/nature10351 · Cited by 1,614 · cited 1×
“The MLL3 mutation or its deletion is found in hematological malignancies, including 15% of DLBCL, MDS, and AML (Mrozek 2008; Pasqualucci et al. 2011; Zhang et al. 2013).”
BackgroundThe genetic basis of early T-cell precursor acute lymphoblastic leukaemia
Zhang, J., Ding, L., Holmfeldt, L., Wu, G., Heatley, S. L., Payne-Turner, D., Easton, J., Chen, X., Wang, J., Rusch, M., et al. (2012) · Nature · doi:10.1038/nature10725 · Cited by 1,596 · cited 9×
“Besides EZH2 inactivating mutations, loss-of-function mutations of the PRC2 core components SUZ12 and EED have also been detected in T-ALL, all of which lead to lower levels of H3K27me3 (Ntziachristos et al. 2012; Simon et al. 2012).”
BackgroundInfluentialFrequent Mutation of BAP1 in Metastasizing Uveal Melanomas
Harbour, J. W., Onken, M. D., Roberson, E. D. O., Duan, S., Cao, L., Worley, L. A., Council, M. L., Matatall, K. A., Helms, C., & Bowcock, A. M. (2010) · Science · doi:10.1126/science.1194472 · Cited by 1,462 · cited 1×
“BAP1 is best known for being recurrently mutated in numerous cancers such as mesothelioma, renal cell carcinoma, and metastatic uveal melanoma (Harbour et al. 2010; Bott et al. 2011; Pena-Llopis et al. 2012).”
BackgroundBmi-1 determines the proliferative capacity of normal and leukaemic stem cells.
Lessard, J., & Sauvageau, G. (2003) · Nature · doi:10.1038/nature01572 · Cited by 1,452 · cited 1×
“Over the past decade, a series of studies has implicated PRC1 in HSC self-renewal and differentiation, which require the core subunits of the Bmi1 and Cbx family of proteins (Lessard and Sauvageau 2003; Park et al. 2003; Klauke et al. 2013).”
BackgroundIdentification of pre-leukaemic haematopoietic stem cells in acute leukaemia
Shlush, L. I., Zandi, S., Mitchell, A., Chen, W. C., Brandwein, J. M., Gupta, V., Kennedy, J. A., Schimmer, A. D., Schuh, A. C., Yee, K. W., et al. (2014) · Nature · doi:10.1038/nature13038 · Cited by 1,443 · cited 2×
“4B; Corces-Zimmerman et al. 2014; Shlush et al. 2014).”
BackgroundUTX and JMJD3 are histone H3K27 demethylases involved in HOX gene regulation and development
Agger, K., Cloos, P. A. C., Christensen, J., Pasini, D., Rose, S., Rappsilber, J., Issaeva, I., Canaani, E., Salcini, A. E., & Helin, K. (2007) · Nature · doi:10.1038/nature06145 · Cited by 1,388 · cited 3×
“The chromobox (CBX) proteins have a chromodomain that recognizes the H3K27me3 mark implemented by PRC2 and mediates the chromatin targeting of the canonical PRC1 complex (Cao et al. 2002; Fischle et al. 2003; Min et al. 2003; Agger et al. 2007; Lee et al. 2007).”
BackgroundTet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation
Moran-Crusio, K., Reavie, L., Shih, A., Abdel-Wahab, O., Ndiaye-Lobry, D., Lobry, C., Figueroa, M. E., Vasanthakumar, A., Patel, J., Zhao, X., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.06.001 · Cited by 1,339
Coexistence of Quiescent and Active Adult Stem Cells in Mammals
Li, L., & Clevers, H. (2010) · Science · doi:10.1126/science.1180794 · Cited by 1,247 · cited 1×
“The disruption and misregulation of these processes have the potential to lead to life-threatening hematological disorders (Li and Clevers 2010; Doulatov et al. 2012).”
BackgroundSchlesinger, Y., Straussman, R., Keshet, I., Farkash, S., Hecht, M., Zimmerman, J., Eden, E., Yakhini, Z., Ben-Shushan, E., Reubinoff, B. E., et al. (2007) · Nature Genetics · doi:10.1038/ng1950 · Cited by 1,226
EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer.
Bracken, A. P., Pasini, D., Capra, M., Prosperini, E., Colli, E., & Helin, K. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg542 · Cited by 1,196 · cited 1×
“Their misregulation has been widely linked to multiple disease states in a variety of contexts, particularly in cancers, including hematological malignancies (Varambally et al. 2002; Bracken et al. 2003; Schlesinger et al. 2007; Kondo et al. 2008; Martinez et al. 2009).”
BackgroundInactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders
Ernst, T., Chase, A. J., Score, J., Hidalgo-Curtis, C. E., Bryant, C., Jones, A. V., Waghorn, K., Zoi, K., Ross, F. M., Reiter, A., et al. (2010) · Nature Genetics · doi:10.1038/ng.621 · Cited by 1,139 · cited 9×
“Besides EZH2 inactivating mutations, loss-of-function mutations of the PRC2 core components SUZ12 and EED have also been detected in T-ALL, all of which lead to lower levels of H3K27me3 (Ntziachristos et al. 2012; Simon et al. 2012).”
BackgroundInfluentialDnmt3a is essential for hematopoietic stem cell differentiation
Challen, G. A., Sun, D., Jeong, M., Luo, M., Jelinek, J., Berg, J. S., Bock, C., Vasanthakumar, A., Gu, H., Xi, Y., et al. (2012) · Nature Genetics · doi:10.1038/ng.1009 · Cited by 1,122 · cited 2×
“Hematopoietic-specific disruption of Dnmt3a in mice leads to both increased and decreased DNA methylation at individual loci, and these together contribute to persistent self-renewal and a differentiation block of HSCs (Challen et al. 2012).”
BackgroundShilatifard, A. (2012) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-051710-134100 · Cited by 1,091 · cited 1×
“However, the molecular mechanisms by which MLL chimeras could contribute to the pathogenesis of leukemia were unknown until the biochemical identification of the translocation partner ELL as a transcription elongation factor for RNA polymerase II (Pol II) (Shilatifard et al. 1996; Shilatifard 1998).”
BackgroundSelf-citationMLL Targets SET Domain Methyltransferase Activity to Hox Gene Promoters
Milne, T. A., Briggs, S. D., Brock, H. W., Martin, M. E., Gibbs, D., Allis, C. D., & Hess, J. L. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00741-4 · Cited by 1,053 · cited 1×
“Studies have reported that the wild-type MLL is essential for leukemic transformation byMLL chimeras and that its action is dependent on histone methyltransferase activity (Milne et al. 2010; Cao et al. 2014).”
BackgroundMoore, M. A. S., & Metcalf, D. (1970) · British Journal of Haematology · doi:10.1111/j.1365-2141.1970.tb01443.x · Cited by 1,017 · cited 2×
“TET2 deficiency impedes the overall differentiation potential of HSCs, with a bias toward the expansion of monocyte and macrophage lineages, which is consistent with the myeloid transformation observed in aged mice (Abdel-Wahab et al. 2011; Ko et al. 2011; Moran-Crusio et al. 2011).”
BackgroundGenomewide Analysis of PRC1 and PRC2 Occupancy Identifies Two Classes of Bivalent Domains
Ku, M., Koche, R. P., Rheinbay, E., Mendenhall, E. M., Endoh, M., Mikkelsen, T. S., Presser, A., Nusbaum, C., Xie, X., Chi, A. S., et al. (2008) · PLoS Genetics · doi:10.1371/journal.pgen.1000242 · Cited by 1,009 · cited 1×
“PRC1 and PRC2 co-occupy many PcG target loci and play crucial roles in their reciprocal recruitment to chromatin (Boyer et al. 2006; Schwartz et al. 2006; Ku et al. 2008).”
BackgroundFischle, W., Wang, Y., Jacobs, S. A., Kim, Y., Allis, C. D., & Khorasanizadeh, S. (2003) · Genes & Development · doi:10.1101/gad.1110503 · Cited by 991 · cited 1×
“The chromobox (CBX) proteins have a chromodomain that recognizes the H3K27me3 mark implemented by PRC2 and mediates the chromatin targeting of the canonical PRC1 complex (Cao et al. 2002; Fischle et al. 2003; Min et al. 2003; Agger et al. 2007; Lee et al. 2007).”
BackgroundLohr, J. G., Stojanov, P., Lawrence, M. S., Auclair, D., Chapuy, B., Sougnez, C., Cruz-Gordillo, P., Knoechel, B., Asmann, Y. W., Slager, S. L., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1121343109 · Cited by 974 · cited 6×
“MLL4 (GeneID 8085) mutations are prevalent in NHL (Morin et al. 2011; Pasqualucci et al. 2011; Lohr et al. 2012; Green et al. 2015), ALL (Mar et al.”
BackgroundInfluentialBAP1 loss defines a new class of renal cell carcinoma
Peña-Llopis, S., Vega-Rubín-de-Celis, S., Liao, A., Leng, N., Pavía-Jiménez, A., Wang, S., Yamasaki, T., Zhrebker, L., Sivanand, S., Spence, P., et al. (2012) · Nature Genetics · doi:10.1038/ng.2323 · Cited by 959 · cited 1×
“BAP1 is best known for being recurrently mutated in numerous cancers such as mesothelioma, renal cell carcinoma, and metastatic uveal melanoma (Harbour et al. 2010; Bott et al. 2011; Pena-Llopis et al. 2012).”
BackgroundInactivating mutations of acetyltransferase genes in B-cell lymphoma
Pasqualucci, L., Dominguez-Sola, D., Chiarenza, A., Fabbri, G., Grunn, A., Trifonov, V., Kasper, L. H., Lerach, S., Tang, H., Ma, J., et al. (2011) · Nature · doi:10.1038/nature09730 · Cited by 949 · cited 3×
“MLL4 (GeneID 8085) mutations are prevalent in NHL (Morin et al. 2011; Pasqualucci et al. 2011; Lohr et al. 2012; Green et al. 2015), ALL (Mar et al. 2012; Lindqvist et al. 2015; Neumann et al. 2015), and AML (Kandoth et al. 2013).”
BackgroundQuivoron, C., Couronné, L., Della Valle, V., Lopez, C. K., Plo, I., Wagner-Ballon, O., Do Cruzeiro, M., Delhommeau, F., Arnulf, B., Stern, M.-H., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.06.003 · Cited by 924 · cited 3×
“TET2 mutations have been observed in both myeloid and lymphoid malignancies, suggesting thatmutations in TET2 occur in early hematopoietic progenitors (Quivoron et al. 2011).”
BackgroundSuz12 is essential for mouse development and for EZH2 histone methyltransferase activity
Pasini, D., Bracken, A. P., Jensen, M. R., Denchi, E. L., & Helin, K. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600402 · Cited by 916 · cited 1×
“EED and SUZ12 are essential for the stability of EZH1 and EZH2 and therefore for H3K27 methylation (Pasini et al. 2004; Xie et al. 2014).”
BackgroundHematopoiesis: a human perspective
Doulatov, S., Notta, F., Laurenti, E., & Dick, J. E. (2012) · Cell stem cell · doi:10.1016/j.stem.2012.01.006 · Cited by 895 · cited 1×
“The disruption and misregulation of these processes have the potential to lead to life-threatening hematological disorders (Li and Clevers 2010; Doulatov et al. 2012).”
BackgroundEzh1 and Ezh2 Maintain Repressive Chromatin through Different Mechanisms
Margueron, R., Li, G., Sarma, K., Blais, A., Zavadil, J., Woodcock, C. L., Dynlacht, B. D., & Reinberg, D. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.11.004 · Cited by 884 · cited 1×
“3C;Margueron et al. 2008).”
MLL-Rearranged Leukemia Is Dependent on Aberrant H3K79 Methylation by DOT1L
Bernt, K. M., Zhu, N., Sinha, A. U., Vempati, S., Faber, J., Krivtsov, A. V., Feng, Z., Punt, N., Daigle, A., Bullinger, L., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.06.010 · Cited by 870 · cited 2×
“Genetic deletion ofDot1l or pharmacological inhibition of its methyltransferase activity renders MLL chimeras unable to activate the malignant transcriptional program in mouse models (Okada et al. 2005; Krivtsov et al. 2008; Chang et al. 2010; Bernt et al. 2011; Nguyen et al. 2011; Deshpande et al. 2013).”
BackgroundPCGF Homologs, CBX Proteins, and RYBP Define Functionally Distinct PRC1 Family Complexes
Gao, Z., Zhang, J., Bonasio, R., Strino, F., Sawai, A., Parisi, F., Kluger, Y., & Reinberg, D. (2012) · Molecular Cell · doi:10.1016/j.molcel.2012.01.002 · Cited by 848 · cited 2×
“The composition ofmammalian PRC1 complexes is more variable and is comprised of the E3 ubiquitin ligases for H2A monoubiquitination (RING1A or RING1B) together with either canonical (CBX2/4/7/8, PHC1/2/3, and BMI1/MEL18) or noncanonical (RYBP/YAF2 and PCGF1/3/5/6) proteins (Fig. 3C; Gao et al. 2012; Tavares et al. 201…”
BackgroundBéguelin, W., Popovic, R., Teater, M., Jiang, Y., Bunting, K. L., Rosen, M., Shen, H., Yang, S. N., Wang, L., Ezponda, T., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.04.011 · Cited by 846 · cited 4×
“Transgenic mouse models initially demonstrated that a specific overexpression of EZH2 in lymphocytes is insufficient for lymphomagenesis on its own but can cooperate with Bcl2 or Myc overexpression (Beguelin et al. 2013; Berg et al. 2014).”
BackgroundInfluentialDNA Methylation Signatures Identify Biologically Distinct Subtypes in Acute Myeloid Leukemia
Figueroa, M. E., Lugthart, S., Li, Y., Erpelinck-Verschueren, C., Deng, X., Christos, P. J., Schifano, E., Booth, J., van Putten, W., Skrabanek, L., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.11.020 · Cited by 833 · cited 1×
“Studies have revealed that the normal distribution of methylated cytosines is disrupted in hematologicalmalignancies, and even subtypes of AML have different DNA methylation patterns (Figueroa et al. 2010).”
BackgroundRecurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis
Busque, L., Patel, J. P., Figueroa, M. E., Vasanthakumar, A., Provost, S., Hamilou, Z., Mollica, L., Li, J., Viale, A., Heguy, A., et al. (2012) · Nature Genetics · doi:10.1038/ng.2413 · Cited by 830 · cited 2×
“TET2-deficient mice is very long, and many elderly individuals with an age-related accumulation of TET2 mutations do not necessarily develop leukemia (Quivoron et al. 2011; Busque et al. 2012).”
BackgroundhDOT1L Links Histone Methylation to Leukemogenesis
Okada, Y., Feng, Q., Lin, Y., Jiang, Q., Li, Y., Coffield, V. M., Su, L., Xu, G., & Zhang, Y. (2005) · Cell · doi:10.1016/j.cell.2005.02.020 · Cited by 804 · cited 4×
“2C; Okada et al. 2005; Mohan et al. 2010a,b).”
BackgroundInfluentialAn oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element
Mansour, M. R., Abraham, B. J., Anders, L., Berezovskaya, A., Gutierrez, A., Durbin, A. D., Etchin, J., Lawton, L., Sallan, S. E., Silverman, L. B., et al. (2014) · Science · doi:10.1126/science.1259037 · Cited by 801 · cited 2×
“Furthermore, in a subset of T-cell ALL (TALL), heterozygous acquisition of a short DNA sequence at a noncoding intergenic region creates a binding site for the transcription factor MYB, thereby creating a de novo enhancer to activate allele-specific expression of TAL1 (Mansour et al. 2014).”
BackgroundHistone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB
Scheuermann, J. C., de Ayala Alonso, A. G., Oktaba, K., Ly-Hartig, N., McGinty, R. K., Fraterman, S., Wilm, M., Muir, T. W., & Müller, J. (2010) · Nature · doi:10.1038/nature08966 · Cited by 792 · cited 2×
“Amammalian PR-DUB complex containing BAP1 and ASX-like 1 (ASXL1) or ASXL2 was also biochemically isolated and demonstrated to harbor deubiquitinase activity in vitro (Scheuermann et al. 2010; Dey et al. 2012).”
BackgroundSomatic mutations of the histone H3K27 demethylase gene UTX in human cancer
van Haaften, G., Dalgliesh, G. L., Davies, H., Chen, L., Bignell, G., Greenman, C., Edkins, S., Hardy, C., O'Meara, S., Teague, J., et al. (2009) · Nature Genetics · doi:10.1038/ng.349 · Cited by 784 · cited 2×
“Intriguingly, myeloid leukemia can have inactivating mutations of both PRC2 components and UTX, raising the question of how simultaneous mutations of factors with opposing enzymatic activity can contribute to leukemogenesis (van Haaften et al. 2009; Jankowska et al. 2011).”
BackgroundA histone H3 lysine 27 demethylase regulates animal posterior development
Lan, F., Bayliss, P. E., Rinn, J. L., Whetstine, J. R., Wang, J. K., Chen, S., Iwase, S., Alpatov, R., Issaeva, I., Canaani, E., et al. (2007) · Nature · doi:10.1038/nature06192 · Cited by 783 · cited 1×
“…of the H3K37me3 mark in promoting epigenetic reprogramming in hematological malignancies is further suggested by the high frequency of inactivating mutations of the H3K27me3 demethylase UTX that resides within MLL3/MLL4 COMPASS-like complexes (Agger et al. 2007; Cho et al. 2007; Lan et al. 2007).”
BackgroundA selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells
Knutson, S. K., Wigle, T. J., Warholic, N. M., Sneeringer, C. J., Allain, C. J., Klaus, C. R., Sacks, J. D., Raimondi, A., Majer, C. R., Song, J., et al. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.1084 · Cited by 776 · cited 1×
“3D; Knutson et al. 2012; McCabe et al. 2012b).”
BackgroundDemethylation of H3K27 Regulates Polycomb Recruitment and H2A Ubiquitination
Lee, M. G., Villa, R., Trojer, P., Norman, J., Yan, K.-P., Reinberg, D., Di Croce, L., & Shiekhattar, R. (2007) · Science · doi:10.1126/science.1149042 · Cited by 771 · cited 1×
“The chromobox (CBX) proteins have a chromodomain that recognizes the H3K27me3 mark implemented by PRC2 and mediates the chromatin targeting of the canonical PRC1 complex (Cao et al. 2002; Fischle et al. 2003; Min et al. 2003; Agger et al. 2007; Lee et al. 2007).”
BackgroundRethinking how DNA methylation patterns are maintained
Jones, P. A., & Liang, G. (2009) · Nature Reviews Genetics · doi:10.1038/nrg2651 · Cited by 765 · cited 1×
“4A; Stein et al. 1982; Okano et al. 1998; Jones and Liang 2009).”
BackgroundRegulation of MLL1 H3K4 methyltransferase activity by its core components
Dou, Y., Milne, T. A., Ruthenburg, A. J., Lee, S., Lee, J. W., Verdine, G. L., Allis, C. D., & Roeder, R. G. (2006) · Nature Structural & Molecular Biology · doi:10.1038/nsmb1128 · Cited by 763 · cited 1×
“The methyltransferase activity of MLL requires the formation of a core complex with the WDR5, RBBP5, ASH2L, and DPY30 subunits (abbreviated as WRAD in the literature) (Dou et al. 2006; Patel et al. 2008, 2009).”
BackgroundSomatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes
Nikoloski, G., Langemeijer, S. M. C., Kuiper, R. P., Knops, R., Massop, M., Tönnissen, E. R. L. T. M., van der Heijden, A., Scheele, T. N., Vandenberghe, P., de Witte, T., et al. (2010) · Nature Genetics · doi:10.1038/ng.620 · Cited by 755 · cited 9×
“Besides EZH2 inactivating mutations, loss-of-function mutations of the PRC2 core components SUZ12 and EED have also been detected in T-ALL, all of which lead to lower levels of H3K27me3 (Ntziachristos et al. 2012; Simon et al. 2012).”
BackgroundInfluentialOkosun, J., Bödör, C., Wang, J., Araf, S., Yang, C.-Y., Pan, C., Boller, S., Cittaro, D., Bozek, M., Iqbal, S., et al. (2014) · Nature Genetics · doi:10.1038/ng.2856 · Cited by 734 · cited 3×
“These and related studies suggest that somatic MLL4 (GeneID 8085) mutations are likely to be early events that occur in a common progenitor cell, with additional mutations leading to themore aggressive state (Green et al. 2013, 2015; Okosun et al. 2014; Pasqualucci et al. 2014; Ortega-Molina et al. 2015).”
BackgroundBlackledge, N. P., Farcas, A. M., Kondo, T., King, H. W., McGouran, J. F., Hanssen, L. L. P., Ito, S., Cooper, S., Kondo, K., Koseki, Y., et al. (2014) · Cell · doi:10.1016/j.cell.2014.05.004 · Cited by 731 · cited 1×
“Conversely, noncanonical PRC1-catalyzedH2AK119monoubiquitination is capable of targeting PRC2 to chromatin (Blackledge et al. 2014; Kalb et al. 2014).”
BackgroundGenetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies
Abdel-Wahab, O., Mullally, A., Hedvat, C., Garcia-Manero, G., Patel, J., Wadleigh, M., Malinge, S., Yao, J., Kilpivaara, O., Bhat, R., et al. (2009) · Blood · doi:10.1182/blood-2009-03-210039 · Cited by 727
Nakamura, T., Mori, T., Tada, S., Krajewski, W., Rozovskaia, T., Wassell, R., Dubois, G., Mazo, A., Croce, C. M., & Canaani, E. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00740-2 · Cited by 721 · cited 1×
“Both SEC and DotCom have been shown to directly associate with HoxA9 and Meis1 loci and are required for their overexpression (Okada et al. 2005; Lin et al. 2010; Neff and Armstrong 2013).”
BackgroundBott, M., Brevet, M., Taylor, B. S., Shimizu, S., Ito, T., Wang, L., Creaney, J., Lake, R. A., Zakowski, M. F., Reva, B., et al. (2011) · Nature Genetics · doi:10.1038/ng.855 · Cited by 717 · cited 1×
“BAP1 is best known for being recurrently mutated in numerous cancers such as mesothelioma, renal cell carcinoma, and metastatic uveal melanoma (Harbour et al. 2010; Bott et al. 2011; Pena-Llopis et al. 2012).”
BackgroundCorces-Zimmerman, M. R., Hong, W.-J., Weissman, I. L., Medeiros, B. C., & Majeti, R. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1324297111 · Cited by 705 · cited 2×
“4B; Corces-Zimmerman et al. 2014; Shlush et al. 2014).”
BackgroundYokoyama, A., Somervaille, T. C. P., Smith, K. S., Rozenblatt-Rosen, O., Meyerson, M., & Cleary, M. L. (2005) · Cell · doi:10.1016/j.cell.2005.09.025 · Cited by 688
A Single Oncogenic Enhancer Rearrangement Causes Concomitant EVI1 and GATA2 Deregulation in Leukemia
Gröschel, S., Sanders, M. A., Hoogenboezem, R., de Wit, E., Bouwman, B. A. M., Erpelinck, C., van der Velden, V. H. J., Havermans, M., Avellino, R., van Lom, K., et al. (2014) · Cell · doi:10.1016/j.cell.2014.02.019 · Cited by 687 · cited 1×
“More recently, two independent studies of AML with a chromosomal inversion between GATA2 and EVI1 revealed that this inversion allows for promiscuous activation of EVI1 by a GATA2 enhancer (Groschel et al. 2014; Yamazaki et al. 2014).”
BackgroundYokoyama, A., Wang, Z., Wysocka, J., Sanyal, M., Aufiero, D. J., Kitabayashi, I., Herr, W., & Cleary, M. L. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.13.5639-5649.2004 · Cited by 662 · cited 2×
“2A; Hsieh et al. 2003; Yokoyama et al. 2004).”
BackgroundStructural basis for specific binding of Polycomb chromodomain to histone H3 methylated at Lys 27
Min, J., Zhang, Y., & Xu, R.-M. (2003) · Genes & Development · doi:10.1101/gad.269603 · Cited by 654 · cited 1×
“Furthermore, mouse genetic studies have demonstrated that the SET domain of the wildtype copy of MLL is dispensable for leukemogenesis (Mishra et al. 2014), raising the question of the efficacy of targeting the wild-type copy of MLL for treating MLL chimera-driven leukemia.”
BackgroundHoxa9 transforms primary bone marrow cells through specific collaboration with Meis1a but not Pbx1b
Kroon, E., Krosl, J., Thorsteinsdottir, U., Baban, S., Buchberg, A. M., & Sauvageau, G. (1998) · The EMBO Journal · doi:10.1093/emboj/17.13.3714 · Cited by 640 · cited 1×
“HoxA9 and Meis1 are the bestcharacterized targets of the MLL chimeras, and their simultaneous overexpression was shown to be sufficient for leukemic transformation (Kroon et al. 1998; Buske and Humphries 2000; Zeisig et al. 2004).”
BackgroundComprehensive methylome map of lineage commitment from haematopoietic progenitors
Ji, H., Ehrlich, L. I. R., Seita, J., Murakami, P., Doi, A., Lindau, P., Lee, H., Aryee, M. J., Irizarry, R. A., Kim, K., et al. (2010) · Nature · doi:10.1038/nature09367 · Cited by 636 · cited 1×
“DNA methylation is dynamically regulated during hematopoietic differentiation, and each DNA methyltransferase plays crucial roles in physiological hematopoiesis (Tadokoro et al. 2007; Broske et al. 2009; Trowbridge et al. 2009; Ji et al. 2010; Bock et al. 2012; Challen et al. 2012).”
BackgroundKondo, Y., Shen, L., Cheng, A. S., Ahmed, S., Boumber, Y., Charo, C., Yamochi, T., Urano, T., Furukawa, K., Kwabi-Addo, B., et al. (2008) · Nature Genetics · doi:10.1038/ng.159 · Cited by 620
COMPASS: A complex of proteins associated with a trithorax-related SET domain protein
Miller, T., Krogan, N. J., Dover, J., Erdjument-Bromage, H., Tempst, P., Johnston, M., Greenblatt, J. F., & Shilatifard, A. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.231473398 · Cited by 618 · cited 1×
“As in yeast Set1, the C-terminal SET domain confers histone H3K4 methyltransferase activity to MLL (Milne et al. 2002; Nakamura et al. 2002).”
BackgroundSelf-citationKo, M., Bandukwala, H. S., An, J., Lamperti, E. D., Thompson, E. C., Hastie, R., Tsangaratou, A., Rajewsky, K., Koralov, S. B., & Rao, A. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1112317108 · Cited by 616
The role of mutations in epigenetic regulators in myeloid malignancies
Shih, A. H., Abdel-Wahab, O., Patel, J. P., & Levine, R. L. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3343 · Cited by 611 · cited 1×
“The cooperative effects of TET2 loss with other oncogenic alterations on hematopoietic transformation have been confirmed in mice with the combined loss of Tet2 and the mutation in Flt3 (Shih et al. 2015).”
BackgroundEzh2 controls B cell development through histone H3 methylation and Igh rearrangement
Su, I.-H., Basavaraj, A., Krutchinsky, A. N., Hobert, O., Ullrich, A., Chait, B. T., & Tarakhovsky, A. (2003) · Nature Immunology · doi:10.1038/ni876 · Cited by 611 · cited 1×
“DNA methylation is dynamically regulated during hematopoietic differentiation, and each DNA methyltransferase plays crucial roles in physiological hematopoiesis (Tadokoro et al. 2007; Broske et al. 2009; Trowbridge et al. 2009; Ji et al. 2010; Bock et al. 2012; Challen et al. 2012).”
BackgroundGenome-wide analysis of Polycomb targets in Drosophila melanogaster
Schwartz, Y. B., Kahn, T. G., Nix, D. A., Li, X.-Y., Bourgon, R., Biggin, M., & Pirrotta, V. (2006) · Nature Genetics · doi:10.1038/ng1817 · Cited by 610
Yap, D. B., Chu, J., Berg, T., Schapira, M., Cheng, S.-W. G., Moradian, A., Morin, R. D., Mungall, A. J., Meissner, B., Boyle, M., et al. (2011) · Blood · doi:10.1182/blood-2010-11-321208 · Cited by 606 · cited 1×
“Indeed, recurrent somatic mutations that result in increased EZH2 enzymatic activity have been observed in lymphoma (Morin et al. 2011; Yap et al. 2011; McCabe et al. 2012a).”
BackgroundASXL1 Mutations Promote Myeloid Transformation through Loss of PRC2-Mediated Gene Repression
Abdel-Wahab, O., Adli, M., LaFave, L. M., Gao, J., Hricik, T., Shih, A. H., Pandey, S., Patel, J. P., Chung, Y. R., Koche, R., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.06.032 · Cited by 599
Lin, C., Smith, E. R., Takahashi, H., Lai, K. C., Martin-Brown, S., Florens, L., Washburn, M. P., Conaway, J. W., Conaway, R. C., & Shilatifard, A. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.01.026 · Cited by 573 · cited 2×
“2C; Lin et al. 2010).”
BackgroundSelf-citationGenetics of Follicular Lymphoma Transformation
Pasqualucci, L., Khiabanian, H., Fangazio, M., Vasishtha, M., Messina, M., Holmes, A. B., Ouillette, P., Trifonov, V., Rossi, D., Tabbò, F., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2013.12.027 · Cited by 573 · cited 2×
“These and related studies suggest that somatic MLL4 (GeneID 8085) mutations are likely to be early events that occur in a common progenitor cell, with additional mutations leading to themore aggressive state (Green et al. 2013, 2015; Okosun et al. 2014; Pasqualucci et al. 2014; Ortega-Molina et al. 2015).”
BackgroundChesi, M., Nardini, E., Lim, R. S. C., Smith, K. D., Kuehl, W. M., & Bergsagel, P. L. (1998) · Blood · doi:10.1182/blood.v92.9.3025 · Cited by 572
Tavares, L., Dimitrova, E., Oxley, D., Webster, J., Poot, R., Demmers, J., Bezstarosti, K., Taylor, S., Ura, H., Koide, H., et al. (2012) · Cell · doi:10.1016/j.cell.2011.12.029 · Cited by 555 · cited 2×
“The composition ofmammalian PRC1 complexes is more variable and is comprised of the E3 ubiquitin ligases for H2A monoubiquitination (RING1A or RING1B) together with either canonical (CBX2/4/7/8, PHC1/2/3, and BMI1/MEL18) or noncanonical (RYBP/YAF2 and PCGF1/3/5/6) proteins (Fig. 3C; Gao et al. 2012; Tavares et al. 201…”
BackgroundH3K79 Methylation Profiles Define Murine and Human MLL-AF4 Leukemias
Krivtsov, A. V., Feng, Z., Lemieux, M. E., Faber, J., Vempati, S., Sinha, A. U., Xia, X., Jesneck, J., Bracken, A. P., Silverman, L. B., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.10.001 · Cited by 550 · cited 1×
“…deletion ofDot1l or pharmacological inhibition of its methyltransferase activity renders MLL chimeras unable to activate the malignant transcriptional program in mouse models (Okada et al. 2005; Krivtsov et al. 2008; Chang et al. 2010; Bernt et al. 2011; Nguyen et al. 2011; Deshpande et al. 2013).”
BackgroundRecurrent DNMT3A mutations in patients with myelodysplastic syndromes
Walter, M. J., Ding, L., Shen, D., Shao, J., Grillot, M., McLellan, M., Fulton, R., Schmidt, H., Kalicki-Veizer, J., O'Laughlin, M., et al. (2011) · Leukemia · doi:10.1038/leu.2011.44 · Cited by 527
Genetic heterogeneity of diffuse large B-cell lymphoma
Zhang, J., Grubor, V., Love, C. L., Banerjee, A., Richards, K. L., Mieczkowski, P. A., Dunphy, C., Choi, W., Au, W. Y., Srivastava, G., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1205299110 · Cited by 527 · cited 1×
“The MLL3 mutation or its deletion is found in hematological malignancies, including 15% of DLBCL, MDS, and AML (Mrozek 2008; Pasqualucci et al. 2011; Zhang et al. 2013).”
BackgroundGenetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia
Ntziachristos, P., Tsirigos, A., Vlierberghe, P. V., Nedjic, J., Trimarchi, T., Flaherty, M. S., Ferres-Marco, D., da Ros, V., Tang, Z., Siegle, J., et al. (2012) · Nature Medicine · doi:10.1038/nm.2651 · Cited by 526
PTIP Associates with MLL3- and MLL4-containing Histone H3 Lysine 4 Methyltransferase Complex
Cho, Y.-W., Hong, T., Hong, S., Guo, H., Yu, H., Kim, D., Guszczynski, T., Dressler, G. R., Copeland, T. D., Kalkum, M., et al. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m701574200 · Cited by 526 · cited 2×
“3A; Cho et al. 2007; Herz et al. 2012).”
BackgroundEpigenetic balance of gene expression by Polycomb and COMPASS families
Piunti, A., & Shilatifard, A. (2016) · Science · doi:10.1126/science.aad9780 · Cited by 524 · cited 6×
“…regulated by chromatin modifiers implementing DNA methylation for genomic imprinting, methylation of H3 Lys9 for the establishment of heterochromatin, and methylation of histone H3 at Lys4 or Lys27 for the activation or repression of Hox gene expression, respectively (Piunti and Shilatifard 2016).”
BackgroundInfluentialSelf-citationLee, J.-E., Wang, C., Xu, S., Cho, Y.-W., Wang, L., Feng, X., Baldridge, A., Sartorelli, V., Zhuang, L., Peng, W., et al. (2013) · eLife · doi:10.7554/elife.01503 · Cited by 522 · cited 1×
“Further studies by other laboratories have now confirmed these original findings establishing MLL3 and MLL4 COMPASS as major regulators of enhancer H3K4 function (Kanda et al. 2013; Lee et al. 2013; Smith and Shilatifard 2014).”
ResultEnhanced self-renewal of hematopoietic stem cells mediated by the polycomb gene product Bmi-1
Iwama, A., Oguro, H., Negishi, M., Kato, Y., Morita, Y., Tsukui, H., Ema, H., Kamijo, T., Katoh-Fukui, Y., Koseki, H., et al. (2004) · Immunity · doi:10.1016/j.immuni.2004.11.004 · Cited by 515 · cited 5×
“reduced cellularity in postnatal bone marrow, spleen, and thymus (Core et al. 1997; Iwama et al. 2004).”
BackgroundInfluentialDNMT3A in haematological malignancies
Yang, L., Rau, R., & Goodell, M. A. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3895 · Cited by 509 · cited 2×
“Long before themethylation of lysine residues in histones were recognized as important epigenetic marks, cytosine methylation at the C5 position of mammalian genomic DNA, usually in the context of CpG dinucleotides, was known to have a critical role in the epigenetic processes of genomic imprinting and X inactivation…”
BackgroundValinluck, V., & Sowers, L. C. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3123 · Cited by 501
McCabe, M. T., Graves, A. P., Ganji, G., Diaz, E., Halsey, W. S., Jiang, Y., Smitheman, K. N., Ott, H. M., Pappalardi, M. B., Allen, K. E., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1116418109 · Cited by 483 · cited 2×
“Indeed, recurrent somatic mutations that result in increased EZH2 enzymatic activity have been observed in lymphoma (Morin et al. 2011; Yap et al. 2011; McCabe et al. 2012a).”
BackgroundDNA methylation protects hematopoietic stem cell multipotency from myeloerythroid restriction
Bröske, A.-M., Vockentanz, L., Kharazi, S., Huska, M. R., Mancini, E., Scheller, M., Kuhl, C., Enns, A., Prinz, M., Jaenisch, R., et al. (2009) · Nature Genetics · doi:10.1038/ng.463 · Cited by 478 · cited 2×
“DNA methylation is dynamically regulated during hematopoietic differentiation, and each DNA methyltransferase plays crucial roles in physiological hematopoiesis (Tadokoro et al. 2007; Broske et al. 2009; Trowbridge et al. 2009; Ji et al. 2010; Bock et al. 2012; Challen et al. 2012).”
BackgroundRecognition and potential mechanisms for replication and erasure of cytosine hydroxymethylation
Hashimoto, H., Liu, Y., Upadhyay, A. K., Chang, Y., Howerton, S. B., Vertino, P. M., Zhang, X., & Cheng, X. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks155 · Cited by 477 · cited 2×
“In addition, oxidized derivatives of 5mC by Tet proteins also facilitate passive demethylation by inhibiting DNA binding of DNMT1 during cell division (Fig. 4A; Valinluck and Sowers 2007; Hashimoto et al. 2012).”
BackgroundBmi1 regulates mitochondrial function and the DNA damage response pathway
Liu, J., Cao, L., Chen, J., Song, S., Lee, I. H., Quijano, C., Liu, H., Keyvanfar, K., Chen, H., Cao, L.-Y., et al. (2009) · Nature · doi:10.1038/nature08040 · Cited by 474 · cited 1×
“The homozygous deletion of Bmi1 in mice decreases the number of HSCs by inducing symmetrical division, derepression of the Ink4a–Arf locus (encoding p16INK4A and p19ARF proteins), and generation of ROS andDNAdamage (Park et al. 2003; Iwama et al. 2004; Oguro et al. 2006; Liu et al. 2009).”
BackgroundDisruption of KMT2D perturbs germinal center B cell development and promotes lymphomagenesis
Zhang, J., Dominguez-Sola, D., Hussein, S., Lee, J.-E., Holmes, A. B., Bansal, M., Vlasevska, S., Mo, T., Tang, H., Basso, K., et al. (2015) · Nature Medicine · doi:10.1038/nm.3940 · Cited by 466 · cited 4×
“Although occurring at a lower rate than truncating mutations, missense mutations of MLL4 (GeneID 8085) are found throughout the protein in lymphomas, with many of the missense mutations located in the C-terminal domains impairing the in vitro histone methyltransferase activity of MLL4 (Zhang et al. 2015).”
BackgroundMethodInfluentialMenin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia
Grembecka, J., He, S., Shi, A., Purohit, T., Muntean, A. G., Sorenson, R. J., Showalter, H. D., Murai, M. J., Belcher, A. M., Hartley, T., et al. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.773 · Cited by 462 · cited 3×
“Pharmacological treatment with these inhibitors (MI-2-2 and MI503) in both leukemic cell lines and a mouse model of leukemia led to apoptosis and hematopoietic differentiation, proliferation defects, and reversal of MLL chimeradriven leukemic transcriptional signatures (Fig. 2D; Grembecka et al. 2012; Borkin et al. 20…”
BackgroundMethodHistone H2A monoubiquitination promotes histone H3 methylation in Polycomb repression
Kalb, R., Latwiel, S., Baymaz, H. I., Jansen, P. W. T. C., Müller, C. W., Vermeulen, M., & Müller, J. (2014) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2833 · Cited by 447 · cited 1×
“Conversely, noncanonical PRC1-catalyzedH2AK119monoubiquitination is capable of targeting PRC2 to chromatin (Blackledge et al. 2014; Kalb et al. 2014).”
BackgroundNSD2 Links Dimethylation of Histone H3 at Lysine 36 to Oncogenic Programming
Kuo, A. J., Cheung, P., Chen, K., Zee, B. M., Kioi, M., Lauring, J., Xi, Y., Park, B. H., Shi, X., Garcia, B. A., et al. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.08.042 · Cited by 443 · cited 18×
“(Top panel) Loss-of-function mutations of ASXL1 are frequently detected inCMML,MDS, andMPN, and thesemutations could give rise to activation of an oncogene normally repressed by PRC2-mediated H3K27me3.”
BackgroundInfluentialHu, D., Gao, X., Morgan, M. A., Herz, H.-M., Smith, E. R., & Shilatifard, A. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.01181-13 · Cited by 439 · cited 3×
“3A; Herz et al. 2012, 2014; Hu et al. 2013a).”
BackgroundSelf-citationNUP98–NSD1 links H3K36 methylation to Hox-A gene activation and leukaemogenesis
Wang, G. G., Cai, L., Pasillas, M. P., & Kamps, M. P. (2007) · Nature Cell Biology · doi:10.1038/ncb1608 · Cited by 437 · cited 1×
“Transplantation studies in mice demonstrated that expression of the NUP98–NSD1 chimera sustains self-renewal of myeloid progenitors and is sufficient to induce AML in vivo by preventing the EZH2-dependent silencing of the Hoxa9 and Meis1 proto-oncogenes (Wang et al. 2007).”
BackgroundOrtega-Molina, A., Boss, I. W., Canela, A., Pan, H., Jiang, Y., Zhao, C., Jiang, M., Hu, D., Agirre, X., Niesvizky, I., et al. (2015) · Nature Medicine · doi:10.1038/nm.3943 · Cited by 436 · cited 2×
“…related studies suggest that somatic MLL4 (GeneID 8085) mutations are likely to be early events that occur in a common progenitor cell, with additional mutations leading to themore aggressive state (Green et al. 2013, 2015; Okosun et al. 2014; Pasqualucci et al. 2014; Ortega-Molina et al. 2015).”
BackgroundSelf-citationLorsbach, R. B., Moore, J., Mathew, S., Raimondi, S. C., Mukatira, S. T., & Downing, J. R. (2003) · Leukemia · doi:10.1038/sj.leu.2402834 · Cited by 416 · cited 1×
“Indeed, TET1 was first identified as an MLL fusion partner in rare cases of AML and ALL that have a t(10,11)(q22;q23) translocation (Ono et al. 2002; Lorsbach et al. 2003; Tahiliani et al. 2009).”
BackgroundLoss of the Tumor Suppressor BAP1 Causes Myeloid Transformation
Dey, A., Seshasayee, D., Noubade, R., French, D. M., Liu, J., Chaurushiya, M. S., Kirkpatrick, D. S., Pham, V. C., Lill, J. R., Bakalarski, C. E., et al. (2012) · Science · doi:10.1126/science.1221711 · Cited by 412 · cited 2×
“Consistent with a physical association with Asxl1, Bap1 loss of function also leads to myeloid transformation in mice (Dey et al. 2012; LaFave et al. 2015).”
BackgroundHerranz, D., Ambesi-Impiombato, A., Palomero, T., Schnell, S. A., Belver, L., Wendorff, A. A., Xu, L., Castillo-Martin, M., Llobet-Navás, D., Cordon-Cardo, C., et al. (2014) · Nature Medicine · doi:10.1038/nm.3665 · Cited by 405 · cited 3×
“(D) Inactivating mutations in MLL3, MLL4, UTX, and EZH2 were observed in myeloid leukemias (MDS, chronic myelomonocytic leukemia [CMML], and primary myelofibrosis [PMF]) and T-cell ALL (TALL).”
BackgroundKrogan, N. J., Dover, J., Khorrami, S., Greenblatt, J. F., Schneider, J., Johnston, M., & Shilatifard, A. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.c200023200 · Cited by 403 · cited 1×
“This complex harbors methyltransferase activity specifically toward Lys4 of histone H3 (Miller et al. 2001; Krogan et al. 2002; Shilatifard 2012; Piunti and Shilatifard 2016).”
BackgroundSelf-citationEmbryonic origin of the adult hematopoietic system: advances and questions
Medvinsky, A., Rybtsov, S., & Taoudi, S. (2011) · Development · doi:10.1242/dev.040998 · Cited by 403
Iyer, L. M., Tahiliani, M., Rao, A., & Aravind, L. (2009) · Cell Cycle · doi:10.4161/cc.8.11.8580 · Cited by 397 · cited 1×
“…of dioxygenases that use oxygen, Fe(II), and a-ketoglutarate as substrates in a sequential enzymatic reaction to convert 5-methylcytosine (5mC) into 5-hydroxymethylcytosine (5hmC) and subsequently into 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC) (Iyer et al. 2009; Tahiliani et al. 2009).”
BackgroundPharmacologic Inhibition of the Menin-MLL Interaction Blocks Progression of MLL Leukemia In Vivo
Borkin, D., He, S., Miao, H., Kempinska, K., Pollock, J., Chase, J., Purohit, T., Malik, B., Zhao, T., Wang, J., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.02.016 · Cited by 392 · cited 1×
“2D; Grembecka et al. 2012; Borkin et al. 2015).”
BackgroundHerz, H.-M., Mohan, M., Garruss, A. S., Liang, K., Takahashi, Y.-H., Mickey, K., Voets, O., Verrijzer, C. P., & Shilatifard, A. (2012) · Genes & Development · doi:10.1101/gad.201327.112 · Cited by 388 · cited 4×
“3A; Herz et al. 2012, 2014; Hu et al. 2013a).”
BackgroundInfluentialSelf-citationLoss of BAP1 function leads to EZH2-dependent transformation
LaFave, L. M., Béguelin, W., Koche, R., Teater, M., Spitzer, B., Chramiec, A., Papalexi, E., Keller, M. D., Hricik, T., Konstantinoff, K., et al. (2015) · Nature Medicine · doi:10.1038/nm.3947 · Cited by 381 · cited 2×
“Thus, Ezh2 deletion or inhibition was shown to abrogate myeloid malignancy and mesothelioma induced by Bap1 loss (LaFave et al. 2015).”
BackgroundDNA Methylation Dynamics during In Vivo Differentiation of Blood and Skin Stem Cells
Bock, C., Beerman, I., Lien, W.-H., Smith, Z. D., Gu, H., Boyle, P., Gnirke, A., Fuchs, E., Rossi, D. J., & Meissner, A. (2012) · Molecular Cell · doi:10.1016/j.molcel.2012.06.019 · Cited by 378 · cited 1×
“DNA methylation is dynamically regulated during hematopoietic differentiation, and each DNA methyltransferase plays crucial roles in physiological hematopoiesis (Tadokoro et al. 2007; Broske et al. 2009; Trowbridge et al. 2009; Ji et al. 2010; Bock et al. 2012; Challen et al. 2012).”
BackgroundThe polycomb group gene Ezh2 prevents hematopoietic stem cell exhaustion
Kamminga, L. M., Bystrykh, L. V., de Boer, A., Houwer, S., Douma, J., Weersing, E., Dontje, B., & de Haan, G. (2006) · Blood · doi:10.1182/blood-2005-09-3585 · Cited by 376 · cited 2×
“Forced expression of Ezh2 was found to prevent the exhaustion of the longterm repopulating capacity of HSCs in a serial transplantation assay and cause development of myeloproliferative disease in recipient mice (Kamminga et al. 2006; Herrera- Merchan et al. 2012).”
BackgroundTrowbridge, J. J., Snow, J. W., Kim, J., & Orkin, S. H. (2009) · Cell Stem Cell · doi:10.1016/j.stem.2009.08.016 · Cited by 373 · cited 1×
“…lymphoid lineage revealed its crucial role in early B-cell development, rearrangement of the Igh gene, germinal center formation, and differentiation and survival of CD4+ T help1 (Th1) and Th2 cells (Su et al. 2003; Beguelin et al. 2013; Caganova et al. 2013; Tumes et al. 2013; Zhang et al. 2014).”
BackgroundA gene product required for correct initiation of segmental determination in Drosophila
Struhl, G. (1981) · Nature · doi:10.1038/293036a0 · Cited by 366 · cited 1×
“…lymphoid lineage revealed its crucial role in early B-cell development, rearrangement of the Igh gene, germinal center formation, and differentiation and survival of CD4+ T help1 (Th1) and Th2 cells (Su et al. 2003; Beguelin et al. 2013; Caganova et al. 2013; Tumes et al. 2013; Zhang et al. 2014).”
BackgroundContrasting roles of histone 3 lysine 27 demethylases in acute lymphoblastic leukaemia
Ntziachristos, P., Tsirigos, A., Welstead, G. G., Trimarchi, T., Bakogianni, S., Xu, L., Loizou, E., Holmfeldt, L., Strikoudis, A., King, B., et al. (2014) · Nature · doi:10.1038/nature13605 · Cited by 365
Martinez-Garcia, E., Popovic, R., Min, D.-J., Sweet, S. M. M., Thomas, P. M., Zamdborg, L., Heffner, A., Will, C., Lamy, L., Staudt, L. M., et al. (2011) · Blood · doi:10.1182/blood-2010-07-298349 · Cited by 360 · cited 1×
“Aberrant up-regulation of NSD2 and a subsequent increase of H3K36me2 lead to an altered localization and overall decrease in the levels of H3K27me3 (Kuo et al. 2011; Martinez-Garcia et al. 2011; Popovic et al. 2014).”
BackgroundGreen, M. R., Kihira, S., Liu, C. L., Nair, R. V., Salari, R., Gentles, A. J., Irish, J., Stehr, H., Vicente-Dueñas, C., Romero-Camarero, I., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1501199112 · Cited by 355 · cited 2×
“MLL4 (GeneID 8085) mutations are prevalent in NHL (Morin et al. 2011; Pasqualucci et al. 2011; Lohr et al. 2012; Green et al. 2015), ALL (Mar et al. 2012; Lindqvist et al. 2015; Neumann et al. 2015), and AML (Kandoth et al. 2013).”
BackgroundDnmt3a and Dnmt3b have overlapping and distinct functions in hematopoietic stem cells
Challen, G. A., Sun, D., Mayle, A., Jeong, M., Luo, M., Rodriguez, B., Mallaney, C., Celik, H., Yang, L., Xia, Z., et al. (2014) · Cell Stem Cell · doi:10.1016/j.stem.2014.06.018 · Cited by 354 · cited 1×
“Dnmt3b knockout alone has a negligible impact on HSC function; however, its deletion along with Dnmt3a further enhances the self-renewal versus differentiation of HSCs (Challen et al. 2014).”
BackgroundRegulation of gene transcription by Polycomb proteins
Aranda, S., Mas, G., & Di Croce, L. (2015) · Science Advances · doi:10.1126/sciadv.1500737 · Cited by 336 · cited 3×
“The composition ofmammalian PRC1 complexes is more variable and is comprised of the E3 ubiquitin ligases for H2A monoubiquitination (RING1A or RING1B) together with either canonical (CBX2/4/7/8, PHC1/2/3, and BMI1/MEL18) or noncanonical (RYBP/YAF2 and PCGF1/3/5/6) proteins (Fig. 3C; Gao et al. 2012; Tavares et al. 201…”
BackgroundJankowska, A. M., Szpurka, H., Tiu, R. V., Makishima, H., Afable, M., Huh, J., O'Keefe, C. L., Ganetzky, R., McDevitt, M. A., & Maciejewski, J. P. (2009) · Blood · doi:10.1182/blood-2009-02-205690 · Cited by 331 · cited 1×
“TET2 mutations identified in patients with hematological cancers are usually monoallelic and inactivating, indicating that it acts as an haploinsufficient tumor suppressor during hematopoietic transformation (Abdel-Wahab et al. 2009; Jankowska et al. 2009).”
BackgroundJankowska, A. M., Makishima, H., Tiu, R. V., Szpurka, H., Huang, Y., Traina, F., Visconte, V., Sugimoto, Y., Prince, C., O'Keefe, C., et al. (2011) · Blood · doi:10.1182/blood-2010-10-311019 · Cited by 330 · cited 1×
“Intriguingly, myeloid leukemia can have inactivating mutations of both PRC2 components and UTX, raising the question of how simultaneous mutations of factors with opposing enzymatic activity can contribute to leukemogenesis (van Haaften et al. 2009; Jankowska et al. 2011).”
BackgroundHoxa9 and Meis1 Are Key Targets for MLL-ENL-Mediated Cellular Immortalization
Zeisig, B. B., Milne, T., García-Cuéllar, M.-P., Schreiner, S., Martin, M.-E., Fuchs, U., Borkhardt, A., Chanda, S. K., Walker, J., Soden, R., et al. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.2.617-628.2004 · Cited by 328
An RNA Polymerase II Elongation Factor Encoded by the Human ELL Gene
Shilatifard, A., Lane, W. S., Jackson, K. W., Conaway, R. C., & Conaway, J. W. (1996) · Science · doi:10.1126/science.271.5257.1873 · Cited by 324 · cited 1×
“4B; Corces-Zimmerman et al. 2014; Shlush et al. 2014).”
Self-citationXie, H., Xu, J., Hsu, J. H., Nguyen, M., Fujiwara, Y., Peng, C., & Orkin, S. H. (2014) · Cell Stem Cell · doi:10.1016/j.stem.2013.10.001 · Cited by 322
Green, M. R., Gentles, A. J., Nair, R. V., Irish, J. M., Kihira, S., Liu, C. L., Kela, I., Hopmans, E. S., Myklebust, J. H., Ji, H., et al. (2013) · Blood · doi:10.1182/blood-2012-09-457283 · Cited by 321 · cited 1×
“…related studies suggest that somatic MLL4 (GeneID 8085) mutations are likely to be early events that occur in a common progenitor cell, with additional mutations leading to themore aggressive state (Green et al. 2013, 2015; Okosun et al. 2014; Pasqualucci et al. 2014; Ortega-Molina et al. 2015).”
BackgroundUnique and Independent Roles for MLL in Adult Hematopoietic Stem Cells and Progenitors
Jude, C. D., Climer, L., Xu, D., Artinger, E., Fisher, J. K., & Ernst, P. (2007) · Cell Stem Cell · doi:10.1016/j.stem.2007.05.019 · Cited by 319 · cited 1×
“…as a conditional deletion in postnatal mice with hematopoietic-specific Vav-Cre leads to a multilineage defect in differentiation and a decrease in adult hematopoietic progenitors, with GENES & DEVELOPMENT 2023 a fatal bonemarrow failure occurring at∼3 wk of age (Jude et al. 2007; Gan et al. 2010).”
BackgroundLinking H3K79 trimethylation to Wnt signaling through a novel Dot1-containing complex (DotCom)
Mohan, M., Herz, H.-M., Takahashi, Y.-H., Lin, C., Lai, K. C., Zhang, Y., Washburn, M. P., Florens, L., & Shilatifard, A. (2010) · Genes & Development · doi:10.1101/gad.1898410 · Cited by 313
Self-citationEnhancer biology and enhanceropathies
Smith, E., & Shilatifard, A. (2014) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2784 · Cited by 311 · cited 1×
“ELL is also found in the little elongation complex (LEC), which specifically regulates distinct stages of small nuclear RNA transcription, essential housekeeping functions that are likely compensated for by the wild-type allele of ELL in leukemia (Smith et al. 2011; Hu et al. 2013b).”
BackgroundSelf-citationMLL3 Is a Haploinsufficient 7q Tumor Suppressor in Acute Myeloid Leukemia
Chen, C., Liu, Y., Rappaport, A. R., Kitzing, T., Schultz, N., Zhao, Z., Shroff, A. S., Dickins, R. A., Vakoc, C. R., Bradner, J. E., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.03.016 · Cited by 311 · cited 1×
“A tumor suppressor function of MLL3 has been proven in a mouse model of AML, with a 50% reduction in gene dosage cooperating with other genetic alterations to promote leukemogenesis (Chen et al. 2014).”
BackgroundTargeting MLL1 H3K4 Methyltransferase Activity in Mixed-Lineage Leukemia
Cao, F., Townsend, E. C., Karatas, H., Xu, J., Li, L., Lee, S., Liu, L., Chen, Y., Ouillette, P., Zhu, J., et al. (2014) · Molecular Cell · doi:10.1016/j.molcel.2013.12.001 · Cited by 301 · cited 2×
“…and MM-401) that inhibit the methyltransferase activity of MLL via disruption of its association with WDR5 were developed and have been shown to function by blocking proliferation, induction of apoptosis, and differentiation of the cells expressing MLL-AF9 (Karatas et al. 2013; Cao et al. 2014).”
BackgroundDouglas, J., Hanks, S., Temple, I. K., Davies, S., Murray, A., Upadhyaya, M., Tomkins, S., Hughes, H. E., Trevor Cole, R. P., & Rahman, N. (2003) · The American Journal of Human Genetics · doi:10.1086/345647 · Cited by 301 · cited 1×
“Deletion or loss-of-function mutations involving NSD1 results in Sotos syndrome, an autosomal dominant overgrowth syndrome characterized by a distinctive facial appearance, delayed development, and learning disabilities (Douglas et al. 2003; Turkmen et al. 2003).”
BackgroundTumes, D. J., Onodera, A., Suzuki, A., Shinoda, K., Endo, Y., Iwamura, C., Hosokawa, H., Koseki, H., Tokoyoda, K., Suzuki, Y., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.09.012 · Cited by 291 · cited 1×
“Deletion or loss-of-function mutations involving NSD1 results in Sotos syndrome, an autosomal dominant overgrowth syndrome characterized by a distinctive facial appearance, delayed development, and learning disabilities (Douglas et al. 2003; Turkmen et al. 2003).”
BackgroundLi, Y., Trojer, P., Xu, C.-F., Cheung, P., Kuo, A., Drury, W. J., Qiao, Q., Neubert, T. A., Xu, R.-M., Gozani, O., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.034462 · Cited by 290 · cited 4×
“Although members of the NSD family were initially shown to have enzymatic activity toward multiple residues on histones, subsequent studies demonstrated that these enzymes preferentially implement histone H3K36me2 (Li et al. 2009b; Kuo et al. 2011; Qiao et al. 2011).”
BackgroundInfluentialOno, R., Taki, T., Taketani, T., Taniwaki, M., Kobayashi, H., & Hayashi, Y. (2002) · PubMed · Cited by 278
Global chromatin profiling reveals NSD2 mutations in pediatric acute lymphoblastic leukemia
Jaffe, J. D., Wang, Y., Chan, H. M., Zhang, J., Huether, R., Kryukov, G. V., Bhang, H.-E. C., Taylor, J. E., Hu, M., Englund, N. P., et al. (2013) · Nature Genetics · doi:10.1038/ng.2777 · Cited by 277 · cited 1×
“NSD2 knockdown selectively inhibited the proliferation and xenograft growth of ALL lines harboring the E1099K mutation in NSD2, indicating its requirement for NSD2 mutant ALL (Jaffe et al. 2013).”
BackgroundAn RNA polymerase II elongation factor encoded by the human ELL gene
(1996) · Trends in Genetics · doi:10.1016/0168-9525(96)81441-7 · Cited by 276
DOT1L, the H3K79 methyltransferase, is required for MLL-AF9–mediated leukemogenesis
Nguyen, A. T., Taranova, O., He, J., & Zhang, Y. (2011) · Blood · doi:10.1182/blood-2011-02-334359 · Cited by 275 · cited 2×
“Genetic deletion ofDot1l or pharmacological inhibition of its methyltransferase activity renders MLL chimeras unable to activate the malignant transcriptional program in mouse models (Okada et al. 2005; Krivtsov et al. 2008; Chang et al. 2010; Bernt et al. 2011; Nguyen et al. 2011; Deshpande et al. 2013).”
BackgroundLux, C. T., Yoshimoto, M., McGrath, K., Conway, S. J., Palis, J., & Yoder, M. C. (2008) · Blood · doi:10.1182/blood-2007-08-107086 · Cited by 273 · cited 2×
“1A; Moore and Metcalf 1970; Lux et al. 2008; Orkin and Zon 2008; Baron et al. 2012; Cullen et al. 2014).”
BackgroundMll Has a Critical Role in Fetal and Adult Hematopoietic Stem Cell Self-Renewal
McMahon, K. A., Hiew, S. Y.-L., Hadjur, S., Veiga-Fernandes, H., Menzel, U., Price, A. J., Kioussis, D., Williams, O., & Brady, H. J. M. (2007) · Cell Stem Cell · doi:10.1016/j.stem.2007.07.002 · Cited by 273 · cited 1×
“5) of mouse development (Medvinsky et al. 2011).”
Hsieh, J. J.-D., Cheng, E. H.-Y., & Korsmeyer, S. J. (2003) · Cell · doi:10.1016/s0092-8674(03)00816-x · Cited by 271 · cited 3×
“2A; Hsieh et al. 2003; Yokoyama et al. 2004).”
BackgroundAltered cellular proliferation and mesoderm patterning in Polycomb-M33-deficient mice
Coré, N., Bel, S., Gaunt, S. J., Aurrand-Lions, M., Pearce, J., Fisher, A., & Djabali, M. (1997) · Development · doi:10.1242/dev.124.3.721 · Cited by 268
Conrad Hal Waddington: the last Renaissance biologist?
Slack, J. M. W. (2002) · Nature Reviews Genetics · doi:10.1038/nrg933 · Cited by 267 · cited 1×
“MLL chimeras recruit SEC and/or DotCom toMLL target genes, which leads to their aberrant activation throughmisregulation of the transcriptional elongation checkpoint (Smith and Shilatifard 2013).”
BackgroundA key role for EZH2 and associated genes in mouse and human adult T-cell acute leukemia
Simon, C., Chagraoui, J., Krosl, J., Gendron, P., Wilhelm, B., Lemieux, S., Boucher, G., Chagnon, P., Drouin, S., Lambert, R., et al. (2012) · Genes & Development · doi:10.1101/gad.186411.111 · Cited by 264 · cited 1×
“The term “epigenetics” was coined by developmental biologist Conrad Waddington to describe heritable changes in the cellular phenotype and gene expression that are independent of alterations in the DNA sequence during embryonic development (Slack 2002; Berger et al. 2009).”
BackgroundEZH2 mutational status predicts poor survival in myelofibrosis
Guglielmelli, P., Biamonte, F., Score, J., Hidalgo-Curtis, C., Cervantes, F., Maffioli, M., Fanelli, T., Ernst, T., Winkelman, N., Jones, A. V., et al. (2011) · Blood · doi:10.1182/blood-2011-06-363424 · Cited by 262 · cited 3×
“Although an excess of H3K27me3 activity generally has an oncogenic role in cancer, loss-of-function mutations in EZH2 have been detected in a subset of myeloid malignancies, most commonly in MDSs, chronic myelomonocytic leukemia (CMML), primary myelofibrosis (PMF), and T-ALL (Ernst et al. 2010; Nikoloski et al. 2010;…”
BackgroundGerminal center dysregulation by histone methyltransferase EZH2 promotes lymphomagenesis
Caganova, M., Carrisi, C., Varano, G., Mainoldi, F., Zanardi, F., Germain, P.-L., George, L., Alberghini, F., Ferrarini, L., Talukder, A. K., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci70626 · Cited by 258 · cited 1×
“…lymphoid lineage revealed its crucial role in early B-cell development, rearrangement of the Igh gene, germinal center formation, and differentiation and survival of CD4+ T help1 (Th1) and Th2 cells (Su et al. 2003; Beguelin et al. 2013; Caganova et al. 2013; Tumes et al. 2013; Zhang et al. 2014).”
BackgroundDefects in Yolk Sac Hematopoiesis in Mll-Null Embryos
Hess, J. L., Yu, B. D., Li, B., Hanson, R., & Korsmeyer, S. J. (1997) · Blood · doi:10.1182/blood.v90.5.1799 · Cited by 257 · cited 1×
“5, with fetal livers having dramatically reduced numbers of HSCs, indicating an essential role for Mll in embryonic hematopoiesis (Hess et al. 1997; Ernst et al. 2004; McMahon et al. 2007).”
BackgroundArray-based genomic resequencing of human leukemia
Yamashita, Y., Yuan, J., Suetake, I., Suzuki, H., Ishikawa, Y., Choi, Y. L., Ueno, T., Soda, M., Hamada, T., Haruta, H., et al. (2010) · Oncogene · doi:10.1038/onc.2010.117 · Cited by 249
Patel, A., Dharmarajan, V., Vought, V. E., & Cosgrove, M. S. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.014498 · Cited by 248 · cited 1×
“The methyltransferase activity of MLL requires the formation of a core complex with the WDR5, RBBP5, ASH2L, and DPY30 subunits (abbreviated as WRAD in the literature) (Dou et al. 2006; Patel et al. 2008, 2009).”
BackgroundYamazaki, H., Suzuki, M., Otsuki, A., Shimizu, R., Bresnick, E. H., Engel, J. D., & Yamamoto, M. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.008 · Cited by 242 · cited 1×
“More recently, two independent studies of AML with a chromosomal inversion between GATA2 and EVI1 revealed that this inversion allows for promiscuous activation of EVI1 by a GATA2 enhancer (Groschel et al. 2014; Yamazaki et al. 2014).”
BackgroundKlauke, K., Radulović, V., Broekhuis, M., Weersing, E., Zwart, E., Olthof, S., Ritsema, M., Bruggeman, S., Wu, X., Helin, K., et al. (2013) · Nature Cell Biology · doi:10.1038/ncb2701 · Cited by 237 · cited 2×
“Cbx7 is highly expressed in long-term HSCs, and its overexpression enhances HSC self-renewal and induces leukemia, whereas an ectopic expression of Cbx2, Cbx4, or Cbx8 results in differentiation and exhaustion of HSCs, revealed by the competitive transplantation assay (Klauke et al. 2013).”
BackgroundPopovic, R., Martinez-Garcia, E., Giannopoulou, E. G., Zhang, Q., Zhang, Q., Ezponda, T., Shah, M. Y., Zheng, Y., Will, C. M., Small, E. C., et al. (2014) · PLoS Genetics · doi:10.1371/journal.pgen.1004566 · Cited by 237 · cited 1×
“Aberrant up-regulation of NSD2 and a subsequent increase of H3K36me2 lead to an altered localization and overall decrease in the levels of H3K27me3 (Kuo et al. 2011; Martinez-Garcia et al. 2011; Popovic et al. 2014).”
BackgroundShih, A. H., Jiang, Y., Meydan, C., Shank, K., Pandey, S., Barreyro, L., Antony-Debre, I., Viale, A., Socci, N., Sun, Y., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.009 · Cited by 236 · cited 1×
“However, the molecular mechanisms by which MLL chimeras could contribute to the pathogenesis of leukemia were unknown until the biochemical identification of the translocation partner ELL as a transcription elongation factor for RNA polymerase II (Pol II) (Shilatifard et al. 1996; Shilatifard 1998).”
BackgroundClonal inheritance of the pattern of DNA methylation in mouse cells.
Stein, R., Gruenbaum, Y., Pollack, Y., Razin, A., & Cedar, H. (1982) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.79.1.61 · Cited by 235 · cited 1×
“…malignant hematopoiesis PcG proteins were initially identified in Drosophila by mutations that cause homeotic transformations, such as GENES & DEVELOPMENT 2027 leg-to-antenna transformations or the appearance of additional sex combs on the second and third pairs of legs (Lewis 1978; Struhl 1981).”
BackgroundAbdel-Wahab, O., Pardanani, A., Patel, J., Wadleigh, M., Lasho, T., Heguy, A., Beran, M., Gilliland, D. G., Levine, R. L., & Tefferi, A. (2011) · Leukemia · doi:10.1038/leu.2011.58 · Cited by 231
Multiple Interactions Recruit MLL1 and MLL1 Fusion Proteins to the HOXA9 Locus in Leukemogenesis
Milne, T. A., Kim, J., Wang, G. G., Stadler, S. C., Basrur, V., Whitcomb, S. J., Wang, Z., Ruthenburg, A. J., Elenitoba-Johnson, K. S. J., Roeder, R. G., et al. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.05.011 · Cited by 230
The COMPASS Family of H3K4 Methylases in Drosophila
Mohan, M., Herz, H.-M., Smith, E. R., Zhang, Y., Jackson, J., Washburn, M. P., Florens, L., Eissenberg, J. C., & Shilatifard, A. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.06092-11 · Cited by 228 · cited 1×
“MLL3 and MLL4 (KMT2C and KMT2D) comprise one of the three major branches of the COMPASS family in mammals, with the other two major branches represented by MLL/MLL2 (KMT2A/ KMT2B) and SET1A/SET1B (Mohan et al. 2011; Herz et al. 2012; Shilatifard 2012).”
BackgroundSelf-citationOguro, H., Iwama, A., Morita, Y., Kamijo, T., van Lohuizen, M., & Nakauchi, H. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20052477 · Cited by 227
Rearrangement of ALL1 (MLL) in acute myeloid leukemia with normal cytogenetics.
Caligiuri, M. A., Strout, M. P., Lawrence, D. D., Arthur, D., Baer, M., Yu, F., Knuutila, S., Mrózek, K., Oberkircher, A. R., Marcucci, G., et al. (1998) · PubMed · Cited by 224
Hidalgo, I., Herrera-Merchan, A., Ligos, J. M., Carramolino, L., Nuñez, J., Martinez, F., Dominguez, O., Torres, M., & Gonzalez, S. (2012) · Cell Stem Cell · doi:10.1016/j.stem.2012.08.001 · Cited by 222 · cited 1×
“Ezh1 is required for HSCmaintenance, and its conditional loss leads to HSC senescence and impairment of B-cell lymphopoiesis (Hidalgo et al. 2012).”
BackgroundTET1 plays an essential oncogenic role in MLL -rearranged leukemia
Huang, H., Jiang, X., Li, Z., Li, Y., Song, C.-X., He, C., Sun, M., Chen, P., Gurbuxani, S., Wang, J., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1310656110 · Cited by 220 · cited 2×
“Interestingly, studies demonstrated that TET1 is overexpressed in MLL-rearranged leukemia and that TET1 function is required for up-regulating the expression of MLL chimera oncogenic targets such as HOXA9, MEIS1, and PBX3 (Huang et al. 2013a).”
BackgroundChromatin signatures of cancer
Morgan, M. A., & Shilatifard, A. (2015) · Genes & Development · doi:10.1101/gad.255182.114 · Cited by 219 · cited 8×
“Lymphomas can result from the transformation of B or T lymphocytes or natural killer (NK) cells and can be divided into two main types: Hodgkin’s lymphoma and non-Hodgkin’s lymphoma (NHL).”
BackgroundInfluentialSelf-citationInteraction of MLL Amino Terminal Sequences with Menin Is Required for Transformation
Caslini, C., Yang, Z., El-Osta, M., Milne, T. A., Slany, R. K., & Hess, J. L. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2369 · Cited by 214 · cited 1×
“This interaction has been shown to be essential for the leukemic activity ofMLL chimeras through facilitating the recruitment to chromatin (Yokoyama et al. 2004, 2005; Caslini et al. 2007).”
BackgroundSouroullas, G. P., Jeck, W. R., Parker, J. S., Simon, J. M., Liu, J.-Y., Paulk, J., Xiong, J., Clark, K. S., Fedoriw, Y., Qi, J., et al. (2016) · Nature Medicine · doi:10.1038/nm.4092 · Cited by 212 · cited 1×
“DNMT3A mutations have also been detected in patients with MDS andMPN and are associated with an increased risk of progression toAML (Stegelmann et al. 2011;Walter et al. 2011).”
BackgroundThe embryonic origins of erythropoiesis in mammals
Baron, M. H., Isern, J., & Fraser, S. T. (2012) · Blood · doi:10.1182/blood-2012-01-153486 · Cited by 209 · cited 2×
“1A; Moore and Metcalf 1970; Lux et al. 2008; Orkin and Zon 2008; Baron et al. 2012; Cullen et al. 2014).”
BackgroundALL-1 partial duplication in acute leukemia.
Schichman, S. A., Caligiuri, M. A., Gu, Y., Strout, M. P., Canaani, E., Bloomfield, C. D., & Croce, C. M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.13.6236 · Cited by 207 · cited 1×
“In addition to translocations, partial tandem duplications (PTDs) of MLL have been observed in leukemia with a normal karyotype and linked to an unfavorable prognosis after treatment (Caligiuri et al. 1994, 1998; Schichman et al. 1994).”
BackgroundShi, A., Murai, M. J., He, S., Lund, G., Hartley, T., Purohit, T., Reddy, G., Chruszcz, M., Grembecka, J., & Cierpicki, T. (2012) · Blood · doi:10.1182/blood-2012-05-429274 · Cited by 204 · cited 1×
“4B; Tefferi 2011; Shih et al. 2012).”
Tadokoro, Y., Ema, H., Okano, M., Li, E., & Nakauchi, H. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20060750 · Cited by 202 · cited 3×
“…of dioxygenases that use oxygen, Fe(II), and a-ketoglutarate as substrates in a sequential enzymatic reaction to convert 5-methylcytosine (5mC) into 5-hydroxymethylcytosine (5hmC) and subsequently into 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC) (Iyer et al. 2009; Tahiliani et al. 2009).”
BackgroundHigh-Affinity, Small-Molecule Peptidomimetic Inhibitors of MLL1/WDR5 Protein–Protein Interaction
Karatas, H., Townsend, E. C., Cao, F., Chen, Y., Bernard, D., Liu, L., Lei, M., Dou, Y., & Wang, S. (2013) · Journal of the American Chemical Society · doi:10.1021/ja306028q · Cited by 202 · cited 3×
“…and MM-401) that inhibit the methyltransferase activity of MLL via disruption of its association with WDR5 were developed and have been shown to function by blocking proliferation, induction of apoptosis, and differentiation of the cells expressing MLL-AF9 (Karatas et al. 2013; Cao et al. 2014).”
BackgroundLicensed to elongate: a molecular mechanism for MLL-based leukaemogenesis
Mohan, M., Lin, C., Guest, E., & Shilatifard, A. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2915 · Cited by 199 · cited 1×
“MLL3 and MLL4 (KMT2C and KMT2D) comprise one of the three major branches of the COMPASS family in mammals, with the other two major branches represented by MLL/MLL2 (KMT2A/ KMT2B) and SET1A/SET1B (Mohan et al. 2011; Herz et al. 2012; Shilatifard 2012).”
BackgroundSelf-citationDNA-damage-induced differentiation of leukaemic cells as an anti-cancer barrier
Santos, M. A., Faryabi, R. B., Ergen, A. V., Day, A. M., Malhowski, A., Canela, A., Onozawa, M., Lee, J.-E., Callen, E., Gutierrez-Martinez, P., et al. (2014) · Nature · doi:10.1038/nature13483 · Cited by 196 · cited 2×
“In contrast to MLL4-inactivating mutations contributing to lymphomagenesis, recent studies with conditional ablation ofMll4 (Kmt2d; GeneID 381022) in AML cells revealed that Mll4 is essential for MLL-AF9-induced leukemogenesis (Santos et al. 2014).”
BackgroundResultNUP98 is fused to the NSD3 gene in acute myeloid leukemia associated with t(8;11)(p11.2;p15)
Rosati, R., La Starza, R., Veronese, A., Aventin, A., Schwienbacher, C., Vallespi, T., Negrini, M., Martelli, M. F., & Mecucci, C. (2002) · Blood · doi:10.1182/blood.v99.10.3857 · Cited by 195 · cited 1×
“In addition, rare cases of AML and MDS have NUP98– NSD3 fusions, but the functional importance of these fusions remains to be demonstrated (Rosati et al. 2002; Taketani et al. 2009).”
BackgroundDistant liaisons: long-range enhancer–promoter interactions in Drosophila
Dorsett, D. (1999) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(99)00002-7 · Cited by 190 · cited 1×
“…family in enhancer malfunction and hematological malignancies Transcriptional enhancers were originally defined as noncodingDNAsequences that can increase the transcription of cognate genes in a distance-, position-, and orientationindependent manner (Dorsett 1999; Smith and Shilatifard 2014).”
BackgroundOguro, H., Yuan, J., Ichikawa, H., Ikawa, T., Yamazaki, S., Kawamoto, H., Nakauchi, H., & Iwama, A. (2010) · Cell Stem Cell · doi:10.1016/j.stem.2010.01.005 · Cited by 185
Mrózek, K. (2008) · Seminars in Oncology · doi:10.1053/j.seminoncol.2008.04.007 · Cited by 182
A DNMT3A mutation common in AML exhibits dominant-negative effects in murine ES cells
Kim, S. J., Zhao, H., Hardikar, S., Singh, A. K., Goodell, M. A., & Chen, T. (2013) · Blood · doi:10.1182/blood-2013-02-483487 · Cited by 180 · cited 1×
“R882 mutations can induce hypomethylation by disrupting DNMT3A oligomerization (Kim et al. 2013).”
BackgroundGrossmann, V, Kohlmann, A., Zenger, M., Schindela, S., Eder, C., Weissmann, S., Schnittger, S., Kern, W., Müller, M. C., Hochhaus, A., et al. (2011) · Leukemia · doi:10.1038/leu.2010.298 · Cited by 180 · cited 3×
“Although an excess of H3K27me3 activity generally has an oncogenic role in cancer, loss-of-function mutations in EZH2 have been detected in a subset of myeloid malignancies, most commonly in MDSs, chronic myelomonocytic leukemia (CMML), primary myelofibrosis (PMF), and T-ALL (Ernst et al. 2010; Nikoloski et al. 2010;…”
BackgroundAn Mll-Dependent Hox Program Drives Hematopoietic Progenitor Expansion
Ernst, P., Mabon, M., Davidson, A. J., Zon, L. I., & Korsmeyer, S. J. (2004) · Current Biology · doi:10.1016/j.cub.2004.11.012 · Cited by 179 · cited 1×
“5, with fetal livers having dramatically reduced numbers of HSCs, indicating an essential role for Mll in embryonic hematopoiesis (Hess et al. 1997; Ernst et al. 2004; McMahon et al. 2007).”
BackgroundConcurrent loss of Ezh2 and Tet2 cooperates in the pathogenesis of myelodysplastic disorders
Muto, T., Sashida, G., Oshima, M., Wendt, G. R., Mochizuki-Kashio, M., Nagata, Y., Sanada, M., Miyagi, S., Saraya, A., Kamio, A., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20131144 · Cited by 178 · cited 1×
“As in yeast Set1, the C-terminal SET domain confers histone H3K4 methyltransferase activity to MLL (Milne et al. 2002; Nakamura et al. 2002).”
BackgroundScore, J., Hidalgo-Curtis, C., Jones, A. V., Winkelmann, N., Skinner, A., Ward, D., Zoi, K., Ernst, T., Stegelmann, F., Döhner, K., et al. (2012) · Blood · doi:10.1182/blood-2011-07-367243 · Cited by 177 · cited 1×
“Small molecule disruptors of the MLL–menin interaction were identified through high-throughput screening and structure-based design (Grembecka et al. 2012; Shi et al. 2012).”
MethodLoss- and gain-of-function mutations show a Polycomb group function for Ring1A in mice
Lorente, M. D. M., Marcos-Gutiérrez, C., Pérez, C., Schoorlemmer, J., Ramírezp, A., Magin, T., & Vidal, M. (2000) · Development · doi:10.1242/dev.127.23.5093 · Cited by 176
Histone H3 Lysine 79 Methyltransferase Dot1 Is Required for Immortalization by MLL Oncogenes
Chang, M.-J., Wu, H., Achille, N. J., Reisenauer, M. R., Chou, C.-W., Zeleznik-Le, N. J., Hemenway, C. S., & Zhang, W. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-3294 · Cited by 174 · cited 1×
“…deletion ofDot1l or pharmacological inhibition of its methyltransferase activity renders MLL chimeras unable to activate the malignant transcriptional program in mouse models (Okada et al. 2005; Krivtsov et al. 2008; Chang et al. 2010; Bernt et al. 2011; Nguyen et al. 2011; Deshpande et al. 2013).”
BackgroundLeukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l
Deshpande, A. J., Chen, L., Fazio, M., Sinha, A. U., Bernt, K. M., Banka, D., Dias, S., Chang, J., Olhava, E. J., Daigle, S. R., et al. (2013) · Blood · doi:10.1182/blood-2012-11-465120 · Cited by 174 · cited 2×
“Genetic deletion ofDot1l or pharmacological inhibition of its methyltransferase activity renders MLL chimeras unable to activate the malignant transcriptional program in mouse models (Okada et al. 2005; Krivtsov et al. 2008; Chang et al. 2010; Bernt et al. 2011; Nguyen et al. 2011; Deshpande et al. 2013).”
BackgroundMyelodysplastic syndromes are induced by histone methylation–altering ASXL1 mutations
Inoue, D., Kitaura, J., Togami, K., Nishimura, K., Enomoto, Y., Uchida, T., Kagiyama, Y., Kawabata, K. C., Nakahara, F., Izawa, K., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci70739 · Cited by 172 · cited 2×
“3E; Abdel-Wahab et al. 2012; Inoue et al. 2013).”
ResultStructure of WDR5 Bound to Mixed Lineage Leukemia Protein-1 Peptide
Patel, A., Dharmarajan, V., & Cosgrove, M. S. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.c800164200 · Cited by 171 · cited 1×
“The methyltransferase activity of MLL requires the formation of a core complex with the WDR5, RBBP5, ASH2L, and DPY30 subunits (abbreviated as WRAD in the literature) (Dou et al. 2006; Patel et al. 2008, 2009).”
BackgroundThe Structure of NSD1 Reveals an Autoregulatory Mechanism Underlying Histone H3K36 Methylation
Qiao, Q., Li, Y., Chen, Z., Wang, M., Reinberg, D., & Xu, R.-M. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.204115 · Cited by 170 · cited 3×
“Although members of the NSD family were initially shown to have enzymatic activity toward multiple residues on histones, subsequent studies demonstrated that these enzymes preferentially implement histone H3K36me2 (Li et al. 2009b; Kuo et al. 2011; Qiao et al. 2011).”
BackgroundEnhancer Malfunction in Cancer
Herz, H.-M., Hu, D., & Shilatifard, A. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.02.033 · Cited by 166 · cited 3×
“3A; Herz et al. 2012, 2014; Hu et al. 2013a).”
BackgroundSelf-citationCaligiuri, M. A., Schichman, S. A., Strout, M. P., Mrózek, K., Baer, M. R., Frankel, S. R., Barcos, M. P., Herzig, G. P., Croce, C. M., & Bloomfield, C. D. (1994) · PubMed · Cited by 159
Whitman, S. P., Liu, S., Vukosavljevic, T., Rush, L. J., Yu, L., Liu, C., Klisovic, M. I., Maharry, K. S., Guimond, M., Strout, M. P., et al. (2005) · Blood · doi:10.1182/blood-2005-01-0204 · Cited by 153 · cited 1×
“PTD most commonly occurs by insertion of either exons 5–11 or 5–12 into intron 4 of the full-lengthMLL gene, and this leads to a duplicated N-terminal region that harbors both the AT hooks and the CXXC domains (Whitman et al. 2005).”
BackgroundDNMT3A mutations in myeloproliferative neoplasms
Stegelmann, F., Bullinger, L., Schlenk, R. F., Paschka, P., Griesshammer, M., Blersch, C., Kuhn, S., Schauer, S., Döhner, H., & Döhner, K. (2011) · Leukemia · doi:10.1038/leu.2011.77 · Cited by 151 · cited 1×
“Even a single-nucleotide polymorphism in a PU.1 enhancer leads to reduced PU.1 expression that contributes to the development of AML (Steidl et al. 2007).”
Background
Cited by
Mechanisms that regulate the activities of TET proteins
Joshi, K., Liu, S., Breslin S.J., P., & Zhang, J. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04396-x · Cited by 162
Automated in situ chromatin profiling efficiently resolves cell types and gene regulatory programs
Janssens, D. H., Wu, S. J., Sarthy, J. F., Meers, M. P., Myers, C. H., Olson, J. M., Ahmad, K., & Henikoff, S. (2018) · Epigenetics & Chromatin · doi:10.1186/s13072-018-0243-8 · Cited by 73
Polycomb repressive complexes in hematological malignancies
Iwama, A. (2017) · Blood · doi:10.1182/blood-2017-02-739490 · Cited by 55
SALL Proteins; Common and Antagonistic Roles in Cancer
Álvarez, C., Quiroz, A., Benítez-Riquelme, D., Riffo, E., Castro, A. F., & Pincheira, R. (2021) · Cancers · doi:10.3390/cancers13246292 · Cited by 37
Metadata
- Authors
- Hu, D., & Shilatifard, A.
- Venue
- Genes & Development
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2016-09-15
- Volume
- 30
- Issue
- 18
- Pages
- 2021-2041
- ISSN
- 0890-9369 (ISSN-L)
- 1549-5477
- OpenAlex
- W2529821441
- Cited by
- 168
- References
- 251
- Type
- posted content
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.